Mersana Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Mersana Therapeutics, Inc. (MRSN) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-69.19-171.67-204.21-170.06-88.05-28.21-64.26
Depreciation & Amortization1.631.52-0.540.861.011.021.26
Stock Based Compensation16.4621.1421.5218.417.170.000.00
Change in Working Capital-27.48-18.76132.868.265.11-45.424.18
Change in Accounts Receivable0.0030.00-30.000.000.000.000.00
Change in Accounts Payable-2.86-6.080.950.480.940.000.00
Change in Other Working Capital3.42-20.5415.677.824.990.000.00
Other Operating Activities12.713.4722.522.550.154.860.00
Net Cash from Operating Activities-82.34-168.88-49.36-139.99-74.70-67.74-55.22
Investing Activities
Capital Expenditures-0.13-2.172.20-0.65-0.470.61-1.37
Purchases of Investments-133.43122.05-150.520.0037.500.000.00
Sales/Maturities of Investments145.00277.97-150.520.0037.50-26.6988.57
Net Cash from Investing Activities11.44119.88-152.72-0.6537.03-27.2987.20
Financing Activities
Debt Repayment-2.23-0.41-0.27-5.70-0.12-0.090.00
Common Stock Issued5.7895.09153.2945.56230.7392.160.00
Common Stock Repurchased0.000.000.00-0.260.000.000.00
Other Financing Activities0.00-0.150.0023.78-0.204.970.00
Net Cash from Financing Activities4.0994.68153.0263.65230.4197.701.06
Summary
Net Change in Cash-66.8145.68-49.06-76.99192.742.6733.04
Cash at Beginning of Period175.04129.36178.43255.4262.6760.0126.96
Cash at End of Period108.23-168.88129.36178.4362.6760.0160.01
Free Cash Flow-82.34-171.05-51.56-140.64-75.17-68.35-56.59
Supplemental Disclosures
Interest Paid3.473.382.460.430.230.130.00
Income Taxes Paid0.420.000.000.000.000.000.00